How did VERA's R&D expenses trend impact its Q4 2024 operating profit?

Vera Therapeutics' (VERA) Research and Development (R&D) expenses had a significant impact on its operating profit in Q4 2024. The company's R&D expenses for the quarter were $126.17 million, which is a substantial amount. This high level of spending directly reduces the company's operating income, which in Q4 2024 was -$154.08 million. The negative operating income indicates that the company's expenses exceeded its revenues during the quarter, resulting in a net loss of -$152.15 million[^1).

In summary, VERA's high R&D expenses in Q4 2024 contributed to its negative operating profit, reflecting the significant investments the company is making to develop its therapeutic products.

|code|Ticker|Name|Date|R&D Expenses|Operating Income|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|VERA|VERA.O|Vera Therapeutics|2024 Q1|2.32E7|-2.8832E7|-2.8383E7|185|
|VERA|VERA.O|Vera Therapeutics|2024 Q2|2.9311E7|-3.4151E7|-3.3708E7|185|
|VERA|VERA.O|Vera Therapeutics|2024 Q3|4.0314E7|-4.6976E7|-4.6632E7|185|
|VERA|VERA.O|Vera Therapeutics|2024 Q4|3.3347E7|-4.4122E7|-4.3425E7|185|